Home » Business News » 2011 » January » January 25, 2011

Q-Med AB invites to Year-End Report 2010 conference call

January 25, 2011 - London

Q-Med's Year-End Report for the period January-December 2010 will be published at 08.00 a.m. on Monday January 31, 2011, instead of, as earlier announced, on February 11, 2011.

Media and analysts are invited to participate in a press conference at which the report will be presented by Maria Carell, President and CEO and Alexander Kotsinas, CFO.

Time: Monday January 31 at 10:30 a.m. CET.
Conference id: 88 64 11

To join the conference call dial: Sweden +46 8 505 201 14 or UK +44 (0)20 7162 0177.

The slide presentation will be available at and Investors/Presentations.

A recorded version of the presentation will be available for seven working days on tel: Sweden +46 8 505 203 33 or UK +44 (0)20 7031 4064, access code 88 64 11.

Financial information 2011
January 31, Year-End Report January - December 2010
April 27, Interim Report January - March 2011
April 28, Annual General Meeting
July 21, Half Year Financial Report January - June 2011
October 26, Interim Report January - September 2011

Queries should be addressed to:
Camilla Schartau, IR Co-ordinator
Tel: +46 733 87 14 22

Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta® for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: Web:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Q-Med AB via Thomson Reuters ONE


Comment on this story